News Article
Nov 2, 2017
ReViral present Phase 2a update at BIO-Europe

ReViral’s CEO, Eddy Littler, will be presenting an update on their Phase 2a clinical proof of concept study for Respiratory Syncytial Virus on Tuesday November 7th at BIO-Europe partnering meeting. He will be available for one-to-one discussions on ReViral’s future development using the standard partnering meeting arrangements.